Search Results

• • 2 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• NVX-CoV2373, un vaccin a sous-unites proteiques contre l'infection au SRAS-CoV-2.

  Authors:Sabina Vohra-Miller and Ilan S. SchwartzFrom:CMAJ: Canadian Medical Association Journal (Vol. 194, Issue 45) Peer-Reviewed

  Nov. 21, 2022775 words Article 1760L1 Le NVX-CoV2373 (commercialise sous le nom Nuvaxovid) est un vaccin a sous-unites proteiques contre I'infection au SRAS-CoV-2, approuve au Canada pour les adultes incapables de recevoir un vaccin a ARN messager ou qui...

• NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection.

  Authors:Sabina Vohra-Miller and Ilan S. SchwartzFrom:CMAJ: Canadian Medical Association Journal (Vol. 194, Issue 35) Peer-Reviewed

  Sept. 12, 2022610 words Article 2030L1 NVX-CoV2373 (marketed as Nuvaxoid) is a protein-based vaccine against SARS-CoV-2, approved in Canada for adults unable or unwilling to receive an mRNA vaccine Protein-based vaccines have a long history of use that...